The company has not filed an annual or quarterly report since its Q1 FY2023 10-Q, filed May 10, 2023. Its latest SEC filing is a SC 13G/A from Feb 14, 2024.
10-Q for Q1 FY2023, filed May 10, 2023
The sections below describe the company as of the FY2022 annual report.
Develops drug candidates for retinal diseases, including geographic atrophy, earlier age-related macular degeneration and inherited retinal disorders, for patients with vision loss.
10-K for FY2022, filed Mar 1, 2023We are a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with…View ↗
Geographic Atrophy, or GA, which is the advanced stage of AMD and is characterized by marked thinning or atrophy of retinal tissue, leading…View ↗
Our portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus, or AAV, for gene…View ↗
Leber Congenital Amaurosis type 10, or LCA10, which is characterized by severe bilateral loss of vision at or soon after birth; STGD1; and…View ↗
For a potential U.S. launch, the planned sales team would promote ACP to retina specialists; general ophthalmologists and optometrists diagnose patients and refer them to retinal specialists.
10-K for FY2022, filed Mar 1, 2023
10-Q for Q1 FY2023, filed May 10, 2023
−$72.2MView ↗
ACP's target diseases
The latest report adds intermediate AMD to ACP's target diseases; the earlier report listed geographic atrophy and Stargardt disease.
10-K for FY2019, filed Feb 27, 2020 10-K for FY2022, filed Mar 1, 2023GA, which is the advanced stage of AMD, and is characterized by marked thinning or atrophy of retinal tissue, leading to irreversible loss…View ↗
Geographic Atrophy, or GA, which is the advanced stage of AMD and is characterized by marked thinning or atrophy of retinal tissue, leading…View ↗
Competes with Apellis Pharmaceuticals, LumiThera, Gemini Therapeutics, Disc Medicine, Gyroscope Therapeutics, Novartis, IONIS Pharmaceuticals, Roche, Janssen Pharmaceuticals, Hemera Biosciences, Kanaph Therapeutics, NGM Biopharmaceuticals, Allegro Ophthalmics, Alkeus Pharmaceuticals, and Astellas Pharma
10-K for FY2022, filed Mar 1, 2023In February 2023, the FDA approved Apellis Pharmaceuticals, Inc., or Apellis’s, pegylated, synthetic peptide targeting complement protein…View ↗
Loading...
